Trials / Completed
CompletedNCT02076841
Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen
Tolerability and Quality of Life in Patients With Multiple Sclerosis Switched to Intramuscular Interferon Beta 1a Autoinjector (Avonex® PenTM)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate treatment tolerability, adherence and quality of life (QoL) over 1 year in MS (Multiple Sclerosis) participants who have been switched - due to persistent tolerability issues, particularly injection problems - from a subcutaneous injectable disease-modifying treatment (DMT) given several times a week (Rebif, Betaferon or Copaxone) to once weekly Avonex 30 μg given intra-muscularly. Avonex will be applied by the injection device Avonex Pen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | interferon beta-1a | Administered as specified in the treatment arm |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2016-02-01
- Completion
- 2016-10-01
- First posted
- 2014-03-04
- Last updated
- 2017-01-27
Locations
11 sites across 2 countries: Czechia, Switzerland
Source: ClinicalTrials.gov record NCT02076841. Inclusion in this directory is not an endorsement.